Kazia Therapeutics LtdNASDAQ:KZIANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.0048
- TODAY'S CHANGE (%)-0.0152 (-1.4902%)
- Bid / Lots0.9910/ 4
- Ask / Lots1.0100/ 12
- Open / Previous Close1.0000 / 1.0200
- Day Range
- 52 Week Range
- Volume16,749
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZIA |
|---|---|---|
| 09:32 ET | 710 | 1.02 |
| 09:55 ET | 110 | 1.0164 |
| 10:09 ET | 100 | 1.0169 |
| 10:20 ET | 3100 | 1.01 |
| 10:58 ET | 400 | 1.005 |
| 11:00 ET | 150 | 1.005 |
| 11:02 ET | 400 | 1.005 |
| 11:14 ET | 100 | 1.0038 |
| 11:16 ET | 1370 | 1 |
| 11:25 ET | 7143 | 1.01 |
| 12:08 ET | 1299 | 0.9912 |
| 12:14 ET | 1100 | 0.9912 |
| 12:17 ET | 100 | 1.0048 |
Jan 17, 2023
Kazia to Raise AU$4.5 Million in Private Placement of Shares, from 5:18AM ET on Tuesday Jan 17, 2023 by MT Newswires
5:18AM ET on Tuesday Jan 17, 2023 by MT Newswires
Jan 16, 2023
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS, from 7:01AM ET on Monday Jan 16, 2023 by PR Newswire
7:01AM ET on Monday Jan 16, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kazia Therapeutics Ltd | 16.8M | -0.8x | --- |
Quoin Pharmaceuticals Ltd | 12.3M | 0.0x | --- |
Alterity Therapeutics Ltd | 17.2M | -0.2x | --- |
Adial Pharmaceuticals Inc | 12.3M | -0.6x | --- |
Oncorus Inc | 11.7M | -0.2x | --- |
Virpax Pharmaceuticals Inc | 12.4M | -0.6x | --- |
Company Information
Kazia Therapeutics Limited is an Australia-based oncology-focused biotechnology company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.
Contact Information
- Headquarters
- Three International Towers Level 24 , 300 Barangaroo AvenueSYDNEY, NSW, Australia 2000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Iain Ross
- Chief Executive Officer, Executive Director
- James Garner
- Chief Financial Officer
- Karen Krumeich
- Chief Medical Officer
- John Friend
- Clinical & Regulatory Affairs Manager
- Lilischkis Kimberley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.8M |
|---|---|
Revenue (TTM) | $1.5K |
Shares Outstanding | 18.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.10 |
EPS | $-1.32 |
Book Value | $0.95 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 11,332.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,191,709.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
